Czarnetzki B M, Macher E, Behrendt H, Lejeune F
Recent Results Cancer Res. 1982;80:264-8. doi: 10.1007/978-3-642-81685-7_42.
In the search for an improved prognosis in malignant melanoma after radical surgery, randomized trials arae being conducted examining the results of immunostimulation (BCG or levamisole) with chemotherapy dimethyl - triazeno - imidazole - carboxamide (DTIC) in stage I melanoma. So far, no significant differences between the groups are evident. In stage III melanoma, a series of new agents are being rapidly screened and some appear promising. A closer look at the basic immunopathologic process during the growth of melanomas is might lead to a more effective control of this malignancy.
为了改善恶性黑色素瘤根治术后的预后，正在进行随机试验，研究免疫刺激剂（卡介苗或左旋咪唑）联合化疗药物二甲基 - 三氮烯 - 咪唑 - 甲酰胺（DTIC）用于I期黑色素瘤的效果。到目前为止，各治疗组之间尚未发现明显差异。在III期黑色素瘤治疗方面，一系列新药物正在快速筛选，有些药物看起来很有前景。深入研究黑色素瘤生长过程中的基本免疫病理过程可能会带来对这种恶性肿瘤更有效的控制方法。
